These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14987516)

  • 1. [Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy].
    Rojo Conejo P; Ramos Amador JT; García Piñar L; Ruano Fajardo C; Sánchez Granados JM; González Tomé MI; Ruiz Contreras J
    An Pediatr (Barc); 2004 Mar; 60(3):249-53. PubMed ID: 14987516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
    Mora S; Sala N; Bricalli D; Zuin G; Chiumello G; Viganò A
    AIDS; 2001 Sep; 15(14):1823-9. PubMed ID: 11579244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
    HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women.
    McDermott AY; Shevitz A; Knox T; Roubenoff R; Kehayias J; Gorbach S
    Am J Clin Nutr; 2001 Nov; 74(5):679-86. PubMed ID: 11684538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
    AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body composition in HIV-infected patients receiving highly active antiretroviral therapy.
    Chițu-Tișu CE; Barbu EC; Lazăr M; Bojincă M; Tudor AM; Hristea A; Abagiu AO; Ion DA; Bădărău AI
    Acta Clin Belg; 2017 Feb; 72(1):55-62. PubMed ID: 27724840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy.
    Bunders MJ; Frinking O; Scherpbier HJ; van Arnhem LA; van Eck-Smit BL; Kuijpers TW; Zwinderman AH; Reiss P; Pajkrt D
    Clin Infect Dis; 2013 Feb; 56(4):583-6. PubMed ID: 23097583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of bone mineral density in Iranian HIV/AIDS patients.
    Badie BM; Soori T; Kheirandish P; Izadyar S; SeyedAlinagh S; Foroughi M; Rostamian A; Mohraz M
    Acta Med Iran; 2011; 49(7):460-7. PubMed ID: 21960080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
    Mora S; Zamproni I; Beccio S; Bianchi R; Giacomet V; Viganò A
    J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements.
    Pitukcheewanont P; Safani D; Church J; Gilsanz V
    Osteoporos Int; 2005 Nov; 16(11):1393-6. PubMed ID: 15702261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
    Bonjoch A; Figueras M; Estany C; Perez-Alvarez N; Rosales J; del Rio L; di Gregorio S; Puig J; Gómez G; Clotet B; Negredo E;
    AIDS; 2010 Nov; 24(18):2827-33. PubMed ID: 21045635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
    Zuccotti G; Viganò A; Gabiano C; Giacomet V; Mignone F; Stucchi S; Manfredini V; Marinacci F; Mora S
    Bone; 2010 Jun; 46(6):1633-8. PubMed ID: 20211284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.